CA
NZ
UK
AU
IND
US
…
Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Moolec Science SA is a biotechnology company developing gene‑edited cellular immunotherapies and platform technologies; long-term growth drivers include clinical pipeline advancement, platform validation and partnerships as demand for advanced cell therapies expands. Investors may find the company attractive because positive clinical readouts and successful commercialization could support material upside.
Material risks include early-stage clinical and regulatory uncertainty, high cash burn with financing and dilution risk, complex manufacturing and scalability challenges, and intense competition in the cell therapy sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -52.02M | -4.53M | - |
| Net income | -51.79M | -4.53M | - |
| Selling general administrative | 47.67M | 2.52M | - |
| Selling and marketing expenses | - | 0.11M | - |
| Gross profit | -0.14M | - | - |
| Reconciled depreciation | 0.12M | 0.00M | - |
| Ebit | - | -3.65M | -0.96M |
| Ebitda | - | -3.65M | - |
| Depreciation and amortization | - | 0.00M | - |
| Operating income | -52.89M | -3.65M | - |
| Other operating expenses | - | 3.65M | 0.01M |
| Interest expense | 0.16M | 0.00M | - |
| Tax provision | -0.23M | 0.00M | - |
| Interest income | 0.69M | - | - |
| Net interest income | 0.54M | -0.00M | - |
| Income tax expense | - | 0.00M | - |
| Total revenue | 0.91M | 0.00M | - |
| Total operating expenses | 53.80M | 3.65M | - |
| Cost of revenue | 1.05M | - | - |
| Total other income expense net | 0.33M | -0.87M | - |
| Net income from continuing ops | -51.79M | -4.53M | - |
| Net income applicable to common shares | - | -4.53M | -0.96M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 24.05M | 5.69M | 5.88M |
| Intangible assets | 8.52M | 4.60M | 4.60M |
| Total liab | 13.95M | 4.09M | 0.59M |
| Total stockholder equity | 10.11M | 1.60M | 5.29M |
| Other current liab | 1.16M | 2.86M | - |
| Common stock | - | 0.64M | 0.64M |
| Capital stock | 0.38M | 0.64M | 0.64M |
| Retained earnings | -58.62M | -6.83M | -2.31M |
| Good will | 0.25M | - | - |
| Cash | 2.53M | 1.08M | 0.98M |
| Total current liabilities | 12.60M | 4.09M | 0.59M |
| Net debt | 0.12M | -1.08M | -0.98M |
| Short long term debt | 2.55M | - | - |
| Other stockholder equity | - | 7.80M | 6.96M |
| Property plant equipment | - | 0.01M | 0.01M |
| Total current assets | 5.33M | 1.08M | 1.27M |
| Net tangible assets | - | -2.99M | 0.69M |
| Short term investments | 0.31M | - | - |
| Net receivables | 0.36M | - | 0.29M |
| Long term debt | 0.10M | - | - |
| Inventory | 0.47M | - | - |
| Accounts payable | 2.34M | 1.23M | 0.59M |
| Non current assets total | 18.72M | 4.61M | 4.61M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -2.34M | - | - |
| Change to liabilities | - | 0.93M | 0.06M |
| Net borrowings | - | 2.00M | 2.00M |
| Total cash from financing activities | 11.28M | 2.00M | 7.80M |
| Change to operating activities | - | -0.00M | -6.90M |
| Net income | -51.79M | -4.53M | -0.96M |
| Change in cash | 1.43M | 0.10M | 1.96M |
| Begin period cash flow | 1.08M | 0.98M | - |
| End period cash flow | 2.53M | 1.08M | 0.98M |
| Total cash from operating activities | -7.51M | -1.89M | -7.80M |
| Issuance of capital stock | 10.01M | 0.00M | - |
| Depreciation | 0.12M | 0.00M | 0.00M |
| Dividends paid | 0.00M | - | - |
| Change to inventory | 0.07M | - | - |
| Change to account receivables | -0.04M | - | - |
| Other cashflows from financing activities | - | 2.00M | - |
| Change to netincome | - | 1.71M | 0.78M |
| Capital expenditures | 0.18M | 0.00M | 0.00M |
| Change in working capital | 1.73M | 0.93M | - |
| Stock based compensation | 43.80M | 0.84M | - |
| Other non cash items | -1.45M | 0.87M | - |
| Free cash flow | -7.69M | -1.89M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MLEC Moolec Science SA Ordinary Shares |
- -% |
0.85 | - | - | 16.53 | 5.78 | 20.14 | -1.01 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.
17 Boulevarrd F.W. Raiffeisen,, Luxembourg, Luxembourg, 2411
352 26 49 65 65
45
| Name | Title | Year Born |
|---|---|---|
| Mr. Gaston Paladini M.B.A. | Co-Founder, CEO & Director | 1981 |
| Mr. Henk Hoogenkamp Ph.D. | Co-Founder & Chief Product Officer | 1987 |
| Mr. Martin Salinas Ph.D. | Chief of Technology & Co-Founder | 1982 |
| Mr. Jose Lopez Lecube M.B.A. | CFO & Director | 1983 |
| Mr. Amit Dhingra Ph.D. | Chief Science Officer | 1970 |
| Ms. Catalina Jones B.A. | Chief of Staff & Sustainability | 1986 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...